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Objective:We have conducted the first study of the association of interleukin (IL)-10, tumor
necrosis factor alpha (TNF -α), and IL23R-IL12RB2 region single nucleotide polymorphisms
(SNPs) with Behçet’s disease (BD) in Western Algeria.
Methods: A total of 51 BD patients and 96 unrelated controls from West region of Algeria
were genotyped by direct sequencing for 11 SNPs including 2 SNPs from the IL10 promoter
[c.-819T>C (rs1800871), c.-592A>C (rs1800872)], 6 SNPs from the TNF -α promoter [c.-
1211T>C (rs1799964), c.-1043C>A (rs1800630), c.-1037C>T (rs1799724), c.-556G>A
(rs1800750), c.-488G>A (rs1800629), and c.-418G>A (rs361525)], and 3 SNPs from the
IL23R-IL12RB2 region [g.67747415A>C (rs12119179), g.67740092G>A (rs11209032), and
g.67760140T>C (rs924080)].
Results:The minor alleles c.-819T and c.-592A were significantly associated with BD [odds
ratio (OR)=2.18; 95% confidence interval (CI) 1.28–3.73, p=0.003]; whereas, there was
weaker association between TNF -α promoter SNPs or IL23R-IL12RB2 region and disease
risk.
Conclusion: Unlike the TNF -α and the IL23R-IL12RB2 region SNPs, the two IL10 SNPs
were strongly associated with BD.The -819T, and -592A alleles and the -819TT, -819CT, and
-592AA and -592CA genotypes seem to be highly involved in the risk of developing of BD
in the population of Western Algeria.
Keywords: Behçet’s disease, genetic association, IL10, TNF -α, IL23R -IL12RB2, single nucleotide polymorphism,
Western Algeria
INTRODUCTION
Behçet’s disease (BD) is a systemic inflammatory multifactorial
disease (1). It is characterized by recurrent episodes of oral and
genital ulceration, skin, and ocular lesions (2). The disease is now
recognized as a systemic vasculitis, given that it can affect other
tissues and organs including blood vessels, the digestive tract, and
nervous system (3, 4).
The etiology of BD is not fully elucidated. There is a hypoth-
esis that a pathogenic autoimmune process of BD is triggered
by an infectious or environmental agent, in individuals geneti-
cally predisposed (5). The most strongly genetic factor associated
with the disease is HLA B51 (5, 6). This association was initially
described in 1973 (7) and subsequently confirmed in different
ethnic groups (6, 8, 9).
However, the association between BD and HLA B51 represents
only 20% in the siblings of patients with the disease (10), and
50% of cases with BD are negative for this allele (8, 9). These
observations suggest the existence of other risk factors outside
the HLA region. In fact, several recent genome-wide association
studies have identified additional and new genomic regions that
predispose to the disease (11–14).
The BD causes inflammation and chronic immune activation
within small blood vessels (15–17). The site of inflammation is
usually characterized by infiltration of immune cells as well as by
highly elevated levels of different cytokines (18). IL-10 is one of
the most important cytokines that has been observed at increased
level in the serum and active lesions of BD patients (19–21). TNF-
α and soluble TNF-α receptors are also elevated in the sera of
patients with BD (22–24). Both IL-10 and TNF-α cytokines have
been shown to play an important role in the immunopathol-
ogy of autoimmune diseases (25–28), and an opposite roles in
the inflammatory responses (29, 30). An autoregulatory loop
appears to exist in whereby TNF-α induces IL-10 production,
which ultimately reduces TNF-α synthesis (31, 32). It has been
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suggested that the increase of IL-10 may down-regulate the expres-
sion of NO, prompting the protective role of elevation of IL-10
(33). Additionally, treatment with anti-TNF-α monoclonal anti-
bodies has resulted in improvement of various manifestations
of BD (34, 35).
IL-10 and TNF-α production may be regulated at the tran-
scriptional level. Thus, several single nucleotide polymorphisms
(SNPs) at the promoter of IL10 and TNF-α gene have been shown
to be associated with changes in the expression levels of IL-10 and
TNF-α production (36, 37). On the other hand, numerous recent
studies have demonstrated an association between BD and several
IL10 (13, 14, 38, 39) and TNF-α (39–43) SNPs in different eth-
nic groups. However, to date, there are no analogous or identical
investigations in Algeria.
Two others cytokines, IL-23 and IL-12, may play an impor-
tant role in BD pathogenesis; their levels are elevated in BD
patients (44–46). IL-23 drives and promotes the development
of a unique T-helper cell population that produces IL-17,
Th17 cells. These IL-23-driven Th17 cells are highly patho-
genic and elicit IL-17-dependent inflammation in autoimmune
diseases (47). IL-12, a heterodimeric cytokine, is of crucial
relevance to cell-mediated immunity and Th1 differentiation
(48). This cytokine exerts its biological effects via binding to
a heterodimeric receptor consisting of IL12RB2 and IL-12RB1
subunits.
The effect of IL-23 and IL-12 is mediated through the IL-
23 and the IL-12 receptor (IL-23R, IL-12RB1). The genes that
encode these receptors are adjacent on chromosome 1p31; a GWAS
Studies revealed that IL23R-IL12RB2 region is associated with
BD (13, 14). Nevertheless, its association in the pathogenesis of
BD remains to be confirmed in different ethnic groups. In this
context, we examined genetic association for 11 SNPs in IL10,
TNF-α, and IL23R-IL12RB2 candidate genes with BD in Western
Algeria.
MATERIALS AND METHODS
PATIENTS AND SUBJECTS
Fifty-one (51) unrelated BD patients and age- and sex-matched 96
healthy controls originate from the Western Algeria were recruited
for a case-control study at the Oran Ophthalmic Hamou Boutlelis
Hospital, the Department of Dermatology of Oran Medical Cen-
tre University, and the Oran Blood Transfusion Centre (Algeria).
Among the 51 patients, 11 DNA belonging to Algerian origin,
were selected from the biobank DNA for Genetics Laboratory
of Autoinflammatory Diseases, Arnaud de Villeneuve Hospital,
Montpellier (France).
Consent was signed by each participant or participant’s parent
or legal guardian if entrant is a minor, under the Rules of Ethics
and Professional Conduct. Patient characteristics were recorded
using a questionnaire. The diagnosis of patients was based espe-
cially on the criteria proposed in 1990 (49). The control group was
composed of healthy subjects without a family history of autoin-
flammatory diseases, and selected from the same population. This
work was approved by the Institutional Ethics Board of Tlemcen
Abou-Bekr Belkaïd University.
GENOTYPING
Each DNA was genotyped for 11 SNPs, including two
IL10 promoter SNPs [c.-819T>C (rs1800871), c.-592A>C
(rs1800872)], six SNPs from the TNF-α promoter [c.-
1211T>C (rs1799964), c.-1043C>A (rs1800630), c.-1037C>T
(rs1799724), c.-556G>A (rs1800750), c.-488G>A (rs1800629),
and c.-418G>A (rs361525)], and three SNPs from the IL23R-
IL12RB2 region [g.67747415A>C (rs12119179),g.67740092G>A
(rs11209032), and g.67760140T>C (rs924080)].
Genotyping was performed at the Laboratory of Genetics
of Autoinflammatory Diseases, Arnaud de Villeneuve Hospital,
Montpellier (France). Genomic DNA was isolated from periph-
eral blood, drawed on EDTA anti-coagulant, using QIAamp DNA
Blood Kits (Qiagen, Valencia, CA, USA). The DNA samples were
then dosed by spectrophotometry ND-1000 (Nano Drop Tech-
nologies, Wilmington, DE, USA) at 260 and 280 nm. The DNA
concentration and ratio OD260/OD280 were estimated for each
sample (50).
The DNA samples were subsequently amplified in a Applied
Biosystems Thermocycler (Applied Biosystems, Foster City, CA,
USA) in a 15µL reaction volume containing 50 ng DNA,
2X Promega PCR Master Mix, and 25µM of each primer
(Table 1). The PCR programs were as follows: after a denat-
uration phase of 15 min at 95°C, the samples were subjected
to 35 amplification cycles followed by a final elongation step
of 7 min at 72°C. Each cycle comprises 30 s denaturation at
95°C, 30 s of primer annealing at 60°C, and 1 min extension
at 72°C.
Table 1 | Primers sequence and length product.
Loci SNPs Forward primer Reverse primer Product length (bp)
IL10 rs1800871 rs1800872 TTAGACTCCAGCCACAGAAGC GGGGGACCCAATTATTTCTC 597
TNF-α rs1799964 rs1800630 rs1799724 GTGTGTCTGGGAGTGAGAACTTC CTTCTTTCATTCTGACCCGG 570
rs1800750 rs1800629 rs611525 CTCAGGACTCAACACAGCTTTTC GAAAGAATCATTCAACCAGCG 438
IL23R-IL12RB2 region rs11209032 GGAGTTAAACCTCTTGCTATCCTG GATGCACAATGAGTTGATAAGG 164
rs12119179 TACCCAGGGCATTCAGCTAC GCTTGAGCTCCTGGATCAAG 701
rs924080 GCACGTATGCCTTTTTGCATA ATTTGAATGTGCCTTGGCAT 364
bp, base pair; IL, interleukin; rs, reference SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor.
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After checking the quality and size of the PCR products by
agarose gel (1.5%) electrophoresis, SNPs genotyping was per-
formed by direct sequencing using the BigDye Terminator ver-
sion 3.1 (BDT v3.1) Cycle Sequencing Kit, followed by capillary
electrophoresis on an ABI 3100XL Genetic Analyzer, according to
the manufacturer’s recommendations (Applied Biosystems, Foster
City, CA, USA) (Figure 1).
STATISTICAL ANALYSIS
Comparisons of allele and genotype frequencies between groups
(patients versus control subjects, and between the patient’s groups
according to different clinical features) were performed using the
Chi-square or Fisher’s exact tests. The association analysis was
carried out by Odds ratio (OR) and corresponding 95% confi-
dence interval (95% CI). Statistical analyses were performed using
FIGURE 1 | Electropherogram of rs1800871 and rs1800872. rs, reference SNP; SNP, single nucleotide polymorphism.
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GraphPad Prism Version 5.04 (GraphPad Software, Inc., La Jolla,
CA, USA) and Epi Info 2000 Version 1.0 for Windows (Epi Info,
Atlanta, GA, USA) software.
RESULTS
Table 2 shows the description of the clinical characteristics of the
patients with BD of the current study. The mean age (±SD) of the
patients at disease onset was 26± 11 years. Predominant lesions
were oral ulcers (100%), cutaneous lesions (86.27%), genital ulcers
(82.35%), eye lesions (62.74%), and arthritis (58.82%).
The distribution of alleles and genotypes frequencies of
IL10 promoter SNPs c.-819C>T (rs1800871) and c.-592C>A
(rs1800872) showed that the two SNPs were in total linkage dise-
quilibrium in our sample. For this, reason the results of one SNP
c.-819C>T will be considered (Table 3).
The allele frequencies were significantly different in patients
compared to controls. As indicated in Table 3, the frequencies of
c.-819T (rs1800871) allele, and of the -819TT, -819CT (rs1800871)
genotypes were significantly increased in patients than in controls
(p= 0.003 and p= 0.005, respectively). Additionally, these SNPs
Table 2 | Clinical and demographic features of the Behçet patients of
the current study.
Characteristics Frequency (n=51)
Mean age at disease onset±SD (year) 26±11
Sex ratio M/F (%, n) 56.9/43.1 (29/22)
Oral ulcers (%, n) 100 (51)
Genital ulcers (%, n) 82.4 (42)
Cutaneous lesions (%, n) 86.3 (44)
Eye lesions (%, n) 62.7 (32)
Neurological symptoms (%, n) 35.3 (18)
Venous thrombosis (%, n) 25.5 (13)
Arthritis (%, n) 58.8 (30)
Multiplex family (%, n) 35.3 (18)
pediatric case (%, n) 19.6 (10)
consanguinity (%, n) 43.1 (22)
SD, standard deviation.
Table 3 | Allelic and genotypic frequencies of rs1800871 variant in BD
patients and controls.
Alleles and genotypes Frequencies (%) p
Controls (n=96) Cases (n=51)
C 141 (73.4) 57 (55.9) 0.003**
T 51 (26.6) 45 (44.1)
CC 50 (52.1) 17 (33.3) 0.005**
CT 41 (42.7) 23 (45.1)
TT 5 (5.2) 11 (21.6)
BD, Behçet’s disease; SNP, single nucleotide polymorphism; rs, reference SNP.
**p<0.01.
was significantly associated with the disease (c.-819T; OR= 2.18,
95% CI 1.28–3.73, p< 0.01; -819TT and -819CT, OR= 2.17, 95%
CI 1.01–4.69, p< 0.05) (Figure 2).
A subset analysis was performed to examine the difference in
allele frequencies in clinical subsets of BD (Table 4). We observed
a significant association between c.-819T and all classes; never-
theless, the association was slightly lower for the ocular lesion
(OR= 1.55, 95% CI 0.81–2.96, p> 0.05). Additionally, the associ-
ation was more significant for the Genital ulcers (OR= 2.21; 95%
CI 1.29–4.04, p= 0.002).
We reported in Tables 5 and 6 that all IL23R-IL12RB2 SNPs
alleles and genotypes, respectively,were not significantly associated
with the disease (OR> 1, p> 0.05). The minor allele frequencies
were different in the two groups, but this difference did not reach
statistical significance (p> 0.05).
As indicated in Tables 5 and 7, alleles and genotypes of the
TNF-α polymorphisms display similar distributions in patients
and controls (p> 0.05). Except for c.-1037T and c.-488A all others
TNF-α alleles were not associated with BD (OR< 1).
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FIGURE 2 | Odds ratios for associations between IL10 c.-819C>T, and
-819TT, -819CT (rs1800871) with Behçet’s disease. The two SNPs
c.-819C>T and c.-592C>A are in total linkage disequilibrium in our sample;
therefore, the results of only one SNP c.-819C>T is considered. CI,
confidence interval; rs, reference SNP; SNP, single nucleotide
polymorphism.
Table 4 | Association analysis of clinical subclasses with IL10 c.-819T
SNP in patients with Behçet’s disease.
Clinical subset OR 95% CI p
LL UL
Eye disease 1.55 0.81 2.96 0.152
Genital ulcers 2.21 1.29 4.04 0.002**
Skin lesions 2.07 1.17 3.68 0.007**
Arthritis-arthralgia 2.06 1.11 3.81 0.013*
Neurologic signs 2.5 1.18 5.32 0.009**
CI, confidence interval; LL, lower limit; UP, upper limit; OR, odds ratio; SNP, single
nucleotide polymorphism. *p< 0.05, **p<0.01.
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Table 5 | IL23R -IL12RB2 andTNF -α allelic frequencies in patients with Behçet’s disease.
Loci SNPs Alleles frequency
(proportion, %)
OR (95% CI) p
IL23R-IL12RB2 rs12119179 (g.67747415A>C) A C 1.24 (0.72–2.13) 0.415
Patients 67 (65.7) 35 (34.3)
Controls 135 (70.3) 57 (29.7)
rs11209032 (g.67740092G>A) G A 1.18 (0.68–2.03) 0.530
Patients 67 (65.7) 35 (34.3)
Controls 133 (69.3) 59 (30.7)
rs924080 (g.67760140T>C) T C 1.45 (0.87–2.41) 0.133
Patients 54 (52.9) 48 (47.1)
Controls 84 (43.8) 108 (56.3)
TNF -α rs1799964 (c.-1211T>C) T C 0.92 (0.52–1.61) 0.751
Patients 73 (71.6) 29 (28.4)
Controls 134 (69.8) 58 (30.2)
rs1800630 (c.-1043C>A) C A 0.83 (0.41–1.67) 0.584
Patients 86 (84.3) 16 (15.7)
Controls 157 (81.8) 35 (18.2)
rs17999724 (c.-1037C>T) C T 1.01 (0.35–2.84) 0.976
Patients 95 (93.1) 7 (6.9)
Controls 179 (93.3) 13 (6.7)
rs1800750 (c.-556G>A) G A 0.61 (0.14–2.09) 0.402
Patients 98 (96.1) 4 (3.9)
Controls 180 (93.7) 12 (6.3)
rs1800629 (c.-488G>A) G A 1.12 (0.56–2.26) 0.726
Patients 85 (83.3) 17 (16.7)
Controls 163 (84.9) 29 (15.1)
rs361525 (c.-418G>A) G A 0.93 (0.39–2.21) 0.869
Patients 92 (90.2) 10 (9.8)
Controls 172 (89.6) 20 (10.4)
CI, confidence interval; IL23R-IL12RB2, region of the interleukin-23 receptor and interleukin-12 receptor beta 2 chain-encoding gene; OR, odds ratio; rs, reference
SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor.
Table 6 |The distribution of IL23R -IL12RB2 genotypes in patients with Behçet disease.
SNPs Genotype distribution
(frequency, %)
p-Value OR (95% CI) p-value MAF (%) ORMAF (95% CI) p-value
rs12119179 (g.67747415A>C) AA AC CC 0.522 1.13 (0.54–2.35) 0.734 C 1.24 (0.58–2.67) 0.580
Patients 24 (47.1) 19 (37.2) 8 (15.7) 34.31
Controls 48 (50) 39 (40.6) 9 (9.4) 29.69
rs11209032 (g.67740092G>A) GG GA AA 0.721 1.12 (0.57–2.21) 0.744 A 1.18 (0.71–1.97) 0.560
Patients 23 (45.1) 21 (41.2) 7 (13.7) 34.31
Controls 46 (47.9) 41 (42.7) 9 (9.4) 30.73
rs924080 (g.67760140T>C) CC CT TT 0.327 1.46 (0.64–3.35) 0.326 C 1.58 (0.71–3.54) 0.264
Patients 13 (25.5) 22 (43.1) 16 (31.4) 47.1
Controls 32 (33.4) 44 (45.8) 20 (20.8) 56.25
ORs were calculated for the minor versus major alleles. CI, confidence interval; IL23R-IL12RB2, interleukin-23 receptor and interleukin-12 receptor beta 2
chain-encoding gene; MAF, minor allele frequency; ORMAF, OR of the MAF; OR, odds ratio; rs, reference SNP; SNP, single nucleotide polymorphism.
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Table 7 |The distribution ofTNF -α genotypes in patients with Behçet disease.
SNPs Genotype distribution
(frequency, %)
p-Value OR (95% CI) p-value MAF (%) ORMAF (95% CI) p-value
rs1799964 (c.-1211T>C) TT TC CC 0.114 0.67 (0.32–1.4) 0.249 C 0.8 (0.37–1.75) 0.580
Patients 29 (56.9) 15 (29.4) 7 (13.7) 28.43
Controls 45 (46.9) 44 (45.8) 7 (7.29) 30.21
rs1800630 (c.-1043C>A) CC CA AA 0.826 0.79 (0.35–1.78) 0.544 A 0.78 (0.31–1.97) 0.600
Patients 37 (72.5) 12 (23.5) 2 (4) 15.69
Controls 65 (67.7) 27 (28.1) 4 (4.2) 18.23
rs17999724 (c.-1037C>T) CC CT TT ND 1.23 (0.4–3.74) 0.690 T 1.26 (0.34–4.69) 0.733
Patients 44 (86.3) 7 (13.7) 0 (0) 6.86
Controls 83 (86.5) 13 (13.5) 0 (0) 6.77
rs1800750 (c.-556G>A) GG GA AA ND 0.6 (0.13–2.12) 0.388 A 0.6 (0.12–3.07) 0.536
Patients 47 (92.2) 4 (7.8) 0 (0) 3.92
Controls 84 (87.5) 12 (12.5) 0 (0) 6.25
rs1800629 (c.-488G>A) GG GA AA 0.909 1.17 (0.52–2.61) 0.680 A 1.18 (0.47–2.97) 0.721
Patients 35 (68.6) 15 (29.4) 1 (2) 16.67
Controls 69 (71.9) 25 (26) 2 (2.1) 15.1
rs361525 (c.-418G>A) GG GA AA 0.299 0.75 (0.28–2.02) 0.541 A 0.9 (0.29–2.79) 0.849
Patients 43 (84.3) 6 (11.8) 2 (3.9) 9.8
Controls 77 (80.2) 18 (18.8) 1 (1) 10.42
ORs were calculated for the minor versus major alleles. CI, confidence interval; MAF, minor allele frequency; ND, not defined; OR, odds ratio; ORMAF, OR of the MAF;
rs, reference SNP; SNP, single nucleotide polymorphism; TNF, tumor necrosis factor.
DISCUSSION
To date, the etiopathogenesis of BD is not fully elucidated.
Researches in recent decades have shown the complex role of
genetic factors in the development of the disease. We analyze the
association between BD and 11 SNPs in IL10, TNF-α, and IL23R-
IL12RB2 candidate genes in the Western Algeria population.
This is the first report demonstrating that the c.-819T and
c.-592A alleles were associated with BD in Algeria.
Previous genetic studies have shown a strong association of
many IL10 variants with BD in different ethnic groups. Recent
genome-wide association study conducted by Mizuki et al. (14)
in a Japanese cohort, including 612 individuals with BD and 740
unaffected individuals controls from different ethnic groups, has
shown a significant difference between the two groups for five
IL10 SNPs. The two SNPs analyzed in our study showed an asso-
ciation (OR= 2.18, 95% CI 1.28–3.73, p< 0.01). On the other
hand, a strong association has also been highlighted for IL10
rs1518111 (OR= 1.45, 95% CI 1.34–1.58) in a genome-wide study
performed in 311,459 SNPs in 1215 individuals with BD and
1278 healthy controls from Turkey (13). Our results are consis-
tent with those obtained by Wallace et al. (38) who studied the
segregation of two IL10 promoter SNPs, rs1800871 and rs1800896
in 178 cases and 295 controls from two populations, including
Arab Middle East and United Kingdom. A strong association of
the 819T allele has been observed in United Kingdom patients
(OR 1.5, 95% CI 1.1–2).
Our results are, however, in disagreement with those of the
study of Ates et al. (39) in which no significant association was
revealed by exploring three IL10 SNPs (-1082G>A, rs1800896, c.-
819C>T, rs1800871, and c.-592C>A, rs1800872) in 102 patients
with BD and 102 controls from Turkey. These conflicting results
may be explained by ethnic differences.
Several studies have shown the association of the two (c.-
819 C>T, c.-592C>A) studied SNPs with various inflammatory
diseases, but also with cancer (51–53), periodontitis (54), and
docetaxel-induced liver injury (55). These associations suggested
that the two SNPs can play an important role in the expression
of IL10. In fact, it has been previously reported that the SNP c.-
819C>T and/or c.-592C>A alleles affect the transcription of
IL10 (56). Other studies performed on three SNPs at position -
1082 A>G, -819C>T, and -592C>A in the promoter region of
the IL10 gene have shown that the expression levels of IL-10 was
significantly different according to the some haplotypes (57, 58).
Finally, it has been reported that the disease-associated rs1518111
allele seems to be associated with low IL-10 mRNA expression
and protein production (13). Indeed at the SNP rs1518111 locus,
the rate of transcript of the G allele is higher than that of the
A allele and patients homozygous for the A allele produce less
IL-10 than those who are heterozygous or homozygous for the
G allele.
The result of subset analysis suggests that the risk allele might
predispose to genital ulcers, skin lesions, neurologic signs, and
arthritis-arthralgia, but weakly to eye complications; the asso-
ciation was more significant for the genital ulcers (OR= 2.21,
p= 0.002). Our results are in agreement with those of pre-
vious study (21) that showed a variable increase in mRNA
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expression within all BD lesions, including oral and genital ulcers,
pseudofolliculitis lesions, and lesions at the site of pathergy
testing.
Recent GWAS study from Turkey and Japan revealed
IL12R-IL23RB2 SNPs in association with BD. Three SNPs
were strongly associated with the disease, including rs924080
(OR= 1.28, p= 6.69× 10−9) (13), rs12119179 (p= 2.7× 10−8),
and rs1495965 (OR= 1.35, p= 1.9× 10−11) (14), but no signifi-
cant association was found in a Korean cohort.
Our results showed no significant association between
BD and rs12119179, g.67740092G>A (rs11209032), and
g.67760140T>C (rs924080) SNPs in the IL23R-IL12RB2 region.
In Iranian study (59), six SNPs in IL23R-IL12RB2 were found
to be associated with BD; the most significant of which were
rs17375018 (OR= 1.51, p= 1.93× 10−6), rs7517847 (OR= 1.48,
p= 1.23× 10−6), and rs924080 (OR= 1.29, p= 1.78× 10−5).
Others studies have also identified a strong relationship between
polymorphisms of IL23R and BD (60–62). These associations may
suggest an important role of Th17 cells that express the IL-23R on
their surface. Kim et al. (62) studied the interaction of specific
IL17A, IL23R, and STAT4 (signal transducers and activators of
transcription 4) SNPs in intestinal BD Korean patients; they sug-
gest that the IL-23/IL-17 axis plays a significant role in disease
pathogenesis.
IL-12 has been implicated in the pathogenesis of a multi-
tude of diverse autoimmune diseases (63, 64). IL12RB2 con-
stitute a risk factor for primary biliary cirrhosis, with the
reported top associated SNPs mainly located in intronic sequences
(65–67).
The genetic architecture and modularity of human autoim-
mune diseases is very complex. The functional implications
of most of these associations are not yet clarified. Iden-
tify candidate causal SNPs and pathways (ICSN Pathway)
analysis may act as a powerful guide to further research
into the functional and immunological ramifications of these
associations.
No significant associations were found between BD and stud-
ied TNF-α polymorphisms. These SNPs have been studied in
various ethnic groups for possible association with BD. How-
ever, the allelic and genotypic associations of these studies
have been contradictory. In Korean patients, TNF-α c.-1043A
(rs1800630) allele was associated with an increased risk of BD
(OR= 1.4, p= 0.030) (68). However, no significant association
was found in meta-analysis studies for this SNP (42). Addi-
tionally, it has been reported a significant associations between
c.-1037T allele (rs1799724) (OR= 0.76, 95% CI 0.58–0.98), c.-
488G allele (rs1800629) (OR= 1.8, p= 0.010) (68), and c.-418A
allele (rs361525) (OR= 1.51, 95% CI 1.12–2.04) (42), and BD.
Moreover, no significant associations were identified with other
TNF-α promoter polymorphisms, such as c.-1037T (rs1799724),
c.-488A (rs1800629), and c.-556G>A (rs1800750) alleles with BD
in Moroccan patients (43). The TNF-α c.-1211C allele (rs1799964)
presented a significant association with BD in several popu-
lations, including Turkish (p= 0.023) (69), Korean (p= 0.030,
OR= 1.4) (68), and UK white Caucasoid population (RR= 2.3,
p= 0.00004) (40). The frequency of the TNF-α c.-1211C allele was
significantly higher in Behcet’s patients than in healthy controls
in Moroccan and Tunisian populations (OR= 1.65, p= 0.015;
OR= 1.68, p= 0.02, respectively) (41, 43) and in meta-analysis
(OR= 1.35, 95% CI 1.09–1.68) (42). This polymorphism has
been associated with several extra-intestinal manifestations of
Crohn’s disease, including uveitis, erythema nodosum, and large
joint arthropathy (70), all of which are known to be asso-
ciated with BD. Further investigation is necessary to deter-
mine the functional significance of TNF-α c.-1691042C and
how it participates in the inflammatory dysregulation associated
with BD.
Thus, polymorphisms at positions c.-1211T>C, c.-1043C>A,
c.-1037C>T, and c.-488G>A have been associated with
increased transcriptional activity and production of TNF-α in
some studies (37, 71), in contrast to others (72–75). The over
production of TNF-α during the course of BD may result in
other TNF-α polymorphisms or post-transcriptional mecha-
nisms. Furthermore, TNF-α production is not only under the
control of the promoter region of TNF-α, and it may also
result from complex cis and trans interactions among other
cytokines.
TNF-α is encoded in the HLA complex on chromosome 6, a
region that has long been known to be associated with BD. This
gene-dense region, presentes a strong linkage disequilibrium (76).
The association between BD and TNF-α could therefore be a result
of linkage disequilibrium with alleles within this group. So it will
be interesting to investigate other genes polymorphism among this
region in our population.
In conclusion, we replicate the associations between BD and
the SNPs from the IL23R-IL12RB2 region and c.-1037C>T
and c.-488G>A TNF-α promoter SNPs. IL10 promoter SNPs
(rs1800871 and rs1800872) is strongly associated with BD in the
population of the Western Algeria. It would be interesting to study
other SNPs to identify additional associations with BD in the
studied population.
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